Recurrent Tuberculosis Dynamics and Risk Factors

Recurrent tuberculosis arises when individuals develop a new episode of disease after completing an initial course of therapy. This recurrence can result from relapse of dormant bacilli or reinfection with a new strain of Mycobacterium tuberculosis. Host factors such as immunosuppression (notably HIV coinfection), diabetes, malnutrition and lifestyle risks (smoking, alcohol use) elevate susceptibility, while pathogen characteristics—including drug resistance and specific bacterial lineages—affect both relapse probability and transmission potential. Socioeconomic determinants, health-system performance and adherence to treatment regimens further influence recurrence rates. Molecular methods and advanced statistical analyses have refined estimates of relapse versus reinfection proportions, typically finding most recurrences within three years of treatment completion. Tailored follow-up strategies, preventive therapies and emerging immunological or vaccine interventions offer avenues to mitigate global recurrence burdens and curb onward transmission.

Research from Nature Portfolio

A retrospective study of multidrug-resistant tuberculosis patients treated between 2016 and 2021 employed shared frailty survival models to evaluate time to recurrence and its predictors. Lower baseline weight, smoking, alcohol consumption, haemoptysis, pneumonia, rural residence and comorbid chronic diseases were linked to more rapid recurrence, while higher education and older age delayed relapse. The analysis revealed significant clustering effects at the treatment-centre level, underscoring institutional influences on long-term outcomes and highlighting the need for centre-specific follow-up and support strategies.

Recurrent Tuberculosis Dynamics and Risk Factors publication trend

The graph below shows the total number of articles in recurrent tuberculosis dynamics and risk factors across all publications each year (not limited to Nature Index journals).

Technical terms

Relapse: Reactivation of residual Mycobacterium tuberculosis bacilli from the initial infection, leading to disease recurrence without new exposure.

Reinfection: Development of a new tuberculosis episode following exposure to and infection with a different strain after prior successful treatment.

Multidrug-resistant tuberculosis (MDR-TB): Tuberculosis caused by strains of Mycobacterium tuberculosis resistant to at least isoniazid and rifampicin, requiring second-line therapy.

Frailty model: A statistical survival analysis method that accounts for unobserved heterogeneity and clustering effects among individuals or treatment centres.

Whole-genome sequencing: A laboratory technique determining the complete DNA sequence of an organism’s genome, used to differentiate relapse from reinfection and to detect drug resistance mutations.

Cytokine: Small signalling proteins produced by immune cells that regulate inflammation and host defence, examples include interleukin-1β, interferon-γ and tumour necrosis factor-α.

References

1. Endogenous relapse and exogenous reinfection in recurrent pulmonary tuberculosis: A retrospective study revealed by whole genome sequencing. Frontiers in Microbiology (2023).
2. Identifying risk factors for recurrent multidrug resistant tuberculosis based on patient’s record data from 2016 to 2021: retrospective study. Scientific Reports (2024).
3. Epidemiology and treatment outcomes of recurrent tuberculosis in Tanzania from 2018 to 2021 using the National TB dataset. PLOS Neglected Tropical Diseases (2024).
4. Decreased IL-1 β Secretion as a Potential Predictor of Tuberculosis Recurrence in Individuals Diagnosed with HIV. Biomedicines (2024).